Down-regulating the expression of ADCY1 can increase cisplatin resistance in lung cancer cells through the regulation of the promotion of cell proliferation and the inhibition of cell apoptosis; it can also affect cell cycle activity. Here, ADCY1 is linked to lung cancer.